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PharmacokineticTypically, inhaled drugs are rapidly absorbed into the bloodstream, which results in systemic side effects and a
brief residence time in the lungs. PEGylation was evaluated as a novel strategy for prolonging the retention of
small inhaled molecules in the pulmonary tissue. Hydrolysable ester conjugates of PEG1000, PEG2000, mPEG2000,
PEG3400 and prednisolone, amodel drug cleared from the lungswithin a fewminutes, were synthesised and thor-
oughly characterised. The conjugates were stable in buffers with hydrolysis half-lives ranging from 1 h to 70 h,
depending on the pH and level of substitution. With the exception of PEG3400-prednisolone, conjugates did not
induce a signiﬁcant lactate dehydrogenase (LDH) release from Calu-3 cells after a 20 h exposure. Following
nebulisation to isolated perfused rat lungs (IPRL), the PEG2000 and mPEG2000 conjugates reduced the maximum
prednisolone concentration in the perfusate (Cmax) by 3.0 and 2.2 fold, respectively. Moreover, while predniso-
lone was undetectable in the perfusion solution beyond 20 min when the free drug was administered, prednis-
olone concentrations were still quantiﬁable after 40 min following delivery of the conjugates. This study is the
ﬁrst to demonstrate hydrolysable PEG drug ester conjugates are a promising approach for optimising the phar-
macokinetic proﬁle of small drugs delivered by inhalation.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Although drug inhalation is being explored as a non-invasive route
of delivery to the systemic circulation [1], it is currently still mainly
exploited to obtain a therapeutic effect in the lungs as part of the man-
agement of respiratory diseases such as asthma and chronic obstructive
pulmonary disorders (COPD). Amajor limitation of local pulmonary de-
livery is that typical inhaled drugs are small hydrophobic molecules
which exhibit a sub-optimal pharmacokinetic proﬁle characterised by
a high maximum blood concentration (high Cmax) reached within atre for Biomolecular Sciences,
NG7 2RD, United Kingdom.
(C. Bosquillon).
elasis Avenue, Billingham, TS23
. Open access under CC BY-NC-ND licefewminutes (short tmax), coupledwith a rapid elimination from thepul-
monary tissue [2]. This often results in systemic side effects and a short
duration of action in the lungs. Enhancing their lung residence time
would improve the overall therapeutic index of inhaled drugs as well
as decrease their administration frequency [3–6].
Due to the high permeability of the lungs and the presence of
mucociliary clearance in the upper airways, achieving prolonged drug
retention in the pulmonary tissue after administration by inhalation
remains a major challenge [2]. The most common strategy involves de-
creasing the solubility of the drug in the lung ﬂuid so that the absorption
rate is controlled by the slow dissolution of the particles [2,7]. This is not
always a safe approach as poorly soluble particles might cause lung
irritancy or stimulate phagocytosis by alveolar macrophages with the
risk of inducing a foamy phenotype [2,8]. Alternatively, sustained re-
lease formulations such as liposomes [9] and biodegradable polymer-
based particles [10,11] have been successfully developed for pulmonary
drug delivery. Amongst these, nanoparticles appear themost promising
for substantially extending drug residence time in the lungs due to their
ability to escape clearance mechanisms in the respiratory tract [12,13].
However, inhaled nanoparticulate delivery systems raise importantnse.
Scheme 1. Hydrolysis pathways of PEG-prednisolone conjugates.
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tissue [13]. A third strategy to reduce or slow down pulmonary absorp-
tion consists in altering the permeation rate of the therapeutic com-
pound, for instance, by modifying its physico-chemical properties [2].
This might not however be largely applicable through conventional
drug design since the lung distribution and efﬁcacy of the parent com-
pound are likely to be affected. Considering pulmonary absorption de-
creases dramatically with an increase in molecular weight and
hydrophilicity [14,15], a large hydrophilic pro-drug which slowly re-
leases the active molecule in the lung ﬂuid has the potential to improve
its pharmacokinetic proﬁle after inhalation while minimising the im-
pact on the therapeutic response.
For the ﬁrst time, we describe a drug conjugation strategy be-
tween polyethylene glycol (PEG), and a low molecular weight mol-
ecule aiming at optimising the pharmacokinetics of inhaled drugs.
PEG being biocompatible and non toxic [16], PEGylation of both
macromolecules and small drugs is extensively used to enhance
their circulating half-life and/or safety proﬁle after parenteral ad-
ministration [17]. PEG conjugates have recently been developed
to increase the stability of salmon calcitonin in the lung ﬂuid [18] as
well as to improve the biocompatibility of the biphosphonate derivative
alendronate [19] and antimicrobial peptides [20] following pulmonary
administration. In contrast, PEGylation of small inhaled drugs has not
yet been attempted with the objective of prolonging their residence
time in the lungs.
This study evaluates the potential of such an approach using
hydrolysable ester conjugates of PEG and the corticosteroid predniso-
lone, herein used as a model inhaled drug rapidly absorbed from the
lungs. Conjugates of various molecular weights were synthesised and
characterised before their rate of hydrolysis was measured in buffers
over a range of relevant pH. The innocuousness of the molecular con-
structs was veriﬁed in vitro and the ability of selected conjugates to in-
crease pulmonary retention after inhalation was ﬁnally assessed in an
isolated perfused rat lung (IPRL) model.
2. Material and methods
2.1. Materials
TEMPO (2,2,6,6-Tetramethylpiperidine-1-oxyl)was purchased from
Alfa Aesar (Karlsruhe, Germany). Laboratory grade solvents, concen-
trated hydrochloric acid and sodium hydroxide were obtained from
Fisher scientiﬁc (Loughborough, UK) while dry solvents were pur-
chased from Acros Organics (Geel, Belgium). Unless stated otherwise,
all other chemicals were purchased form Sigma-Aldrich (Saint Louis,
MO, USA).
2.2. Synthesis of PEG-prednisolone conjugates
PEG with a molecular weight of 1000, 2000 or 3400 Da and
monomethoxyPEG (mPEG) of 2000 Da were oxidised by sodium hypo-
chlorite inwater, at pH 10 using TEMPO and sodium bromide as catalysts
[21]. The reaction was carried out on ice to maintain the temperature
between 2 and 7 °C. Oxidised products were then protonated in 2 M
HCl, extracted with dichloromethane (DCM) and precipitated in diethyl
ether. Oxidised PEG were reacted with prednisolone and the Mukaiyama
reagent (2-chloro-1-methylpyridinium iodide) under dry conditions
to give esters of PEG and prednisolone. Conjugates of PEG3400 and
mPEG2000 were puriﬁed by crystallisation in isopropanol. PEG1000 and
PEG2000 conjugates were puriﬁed by silica gel chromatography using
acetonitrile for washing and tetrahydrofuran (THF) as the eluant. After
puriﬁcation, all conjugateswere precipitated in diethyl ether. The puriﬁed
products were analysed by Fourier Transform Infrared (FTIR) spectrosco-
py using a Nicolet 380 spectrometer with data processed by OMINIC soft-
ware (Thermo) as well as by elemental microanalysis, using an in-house
analytical service (CE-440 Elemental Analyzer from Exeter Analytical).One Dimensional Nuclear Magnetic Resonance (1D NMR) spectra were
acquired using a Bruker AV(III)400 NMR spectrometer. The spectra
were then analysed using ACDlab software v12.
2.3. Hydrolysis in buffers
Hydrolysis proﬁles were obtained inMcIlvaine buffers at pH 6.2 and
7.4 or phosphate buffer at pH 8.0. The ionic strength of each buffer was
adjusted to 0.5 with KCl. Stock solutions of PEG-prednisolonewere pre-
pared inmethanol at a concentration of 30 mMprednisolone. At time 0,
14.3 μL of stock solution was added to 1 mL of pre-heated buffer. The
resulting solution was thoroughly mixed and maintained at 37 °C
throughout the course of the hydrolysis study. Twentymicrolitre samples
were collected at pre-determined time intervals and directly analysed by
High Performance Liquid Chromatography (HPLC-UV). The HPLC
system consisted of an Agilent 1050, controlled by the Chemstation
software (rev A 08.03, Agilent). The stationary phase was a Gemini
(Phenomenex, Macclesﬁeld, UK) 3 μm, C18 column, 100 × 3 mm
and the mobile phase was a gradient of methanol in water as
follows: 0–0.5 min: 60% methanol; 0.5–1 min: gradient from 60% to
90% methanol; 1–2.5 min: 90% methanol; 2.5–5 min: 60% methanol.
Prednisolone and the conjugates were monitored by UV absorption at
242 nm. Prednisolone eluted at 2.1 min, PEG-Pred2 (disubstituted
PEG, i.e., with a prednisolone molecule attached to each chain end) at
4.0 min and mPEG-Pred (monosubstituted) at 4.4 min. Quantiﬁcation
of free prednisolone and conjugates was performed by measuring
the chromatogram peak areas. The limit of quantiﬁcation was
0.06 μM for the drug and b10 μM for the conjugates, depending on
their composition.
The hydrolysis pathways of the mono and disubstituted conjugates
are illustrated by Scheme 1.
The hydrolysis constant k1 and k2 were determined by the
slope of the plots showing the log of the concentration in conju-
gates with time (ﬁrst order kinetics). Although a low trace signal
of the intermediate −OOC-PEG-Pred was visible on the chromato-
grams at a retention time similar to that of mPEG-Pred, this was
not quantiﬁable by the HPLC-UV method. The Berkeley–Madonna
software (v.8.3.18, the University of California, Berkeley, CA, USA)
was used to calculate the hydrolysis rate constant k3. The soft-
ware solved the system of differential Eq. (1), using the degrada-
tion proﬁles of PEG-Pred2 along with the release proﬁles of
prednisolone in buffers.
d PEG−Pred2½ 
dt
¼−k2 PEG−Pred2½ 
d Pred2½ 
dt
¼ k3 −OOC−PEG−Pred½  þ k2 PEG−Pred2½ 
d −OOC−PEG−Pred½ 
dt
¼ k2 PEG−Pred2½ −k3 −OOC−PEG−Pred½ 
d PEG− COO−ð Þ2
 
dt
¼ k3 −OOC−PEG−Pred½ 
:
8>>>>><
>>>>>:
ð1Þ
The values calculated for the rate constants k3 were consistently
much higher than k2, likely due to the participation of the free carboxyl-
ate of the intermediate compound in the hydrolysis via an intramolecu-
lar acid catalysed or an intramolecular nucleophilic process. This
Scheme 2. Simpliﬁed hydrolysis pathway of PEG-Pred2.
236 F.J.C. Bayard et al. / Journal of Controlled Release 171 (2013) 234–240implied that the concentration of −OOC-PEG-Pred1 could be neglected
and the hydrolysis simpliﬁed according to Scheme 2.
The half-life was deﬁned as the time needed to hydrolyse half of the
conjugates and was calculated according to Eq. (1).
t1=2 ¼
ln2
k
ð1Þ
2.4. Cytotoxicity assays
Human bronchial epithelial Calu-3 cells were obtained from the
American Type Culture Collection (ATCC, Rockville, MD, USA) and used
between passage 20 and 40. They were cultured in Dulbecco's Modiﬁed
Eagle's medium: nutrient mixture F-12 Ham (1:1) supplemented with
10% Foetal Bovine Serum, 100UI mL−1 penicillin and100 μg mL−1 strep-
tomycin, 2 mM glutamine and 1% v/v non-essential amino acids at 37 °C
in a 5%CO2 atmosphere. Calu-3 cellswere seededon tissue culture treated
96 well plates (Corning Costar, HighWycombe, UK) at 1 × 104 cells/well
and maintained at 37 °C/5% CO2 for 24 h before experimentation. Stock
solutions of prednisolone and the conjugates were prepared in ethanol
and diluted to produce solutions of varying prednisolone concentrations
in serum-free medium containing 1% of ethanol. Cells were rinsed with
PBS and exposed to the test solutions for 20 h, at 37 °C, 5% CO2. Lactate
Dehydrogenase (LDH) released from the cells was quantiﬁed using the
Cytotox ONE™ kit (Promega) according to the manufacturer's instruc-
tions after cell supernatant was transferred onto black 96-well plates
(Costar Corning). The ﬂuorescence in each well (λex 560 nm, λem
590 nm)wasmeasured on an Inﬁnite® plate reader (Tecan). LDH release
is expressed as % of maximum release obtained with cells exposed to the
lysis buffer (supplied with the kit) and presented as the average of 6 rep-
licates ± standard deviation (SD).
2.5. Absorption studies in the isolated and perfused rat lung (IPRL)
The procedure for IPRL absorption studies has been described in de-
tail elsewhere [22] and was approved by the local ethics committee.
Brieﬂy,maleWistar rats were administered an overdose of sodiumpen-
tobarbital (0.8 mL at 100 mg mL−1) by intraperitoneal injection. The
animals were exsanguinated and heparin was injected in the heart.
The pulmonary artery was cannulated and the lung perfused at approx-
imately 20 mL min−1 with Krebs–Ringer buffer containing 4% Bovine
Serum Albumin and maintained at 37 °C and pH 7.4 by CO2 bubbling.
The pulmonary vein was cannulated and the silicon tubing exiting the
apex of the heart was connected to an autosampler. The trachea was
also cannulated and the isolated lungs and heart were placed in an artiﬁ-
cial thorax with a negative pressure of−0.4 kPa. The isolated lungs were
maintained at 37 °C and ventilated using a rodent ventilator at a tidal vol-
ume of 2 mL and 75 rpm. A single-pass perfusion method was used and
the perfusate was initially directed to waste. Pulmonary resistance, dy-
namic compliance and examination for oedema were used to assess the
lung integrity for 15 min before the experiment started. Only IPRL prepa-
rations that met preset criteria were used for absorption measurements.
Solutions of prednisolone, PEG2000-prednisolone and mPEG2000-
prednisolone were freshly prepared in 25% ethanol then diluted four
times to reach a ﬁnal concentration of 2 mg mL−1 prednisolone. To
maintain similar osmotic properties, prednisolone solutions were
complemented with the same amount of PEG used for the conjugates.
For each experiment, 1 mL of solution for inhalation was transferred
to an Aeroneb Lab nebuliser (control module AG-AL7000, 2.5–4.0 μm
mesh size, nebuliser head AG-AL 1100) and nebulised into a 500 mL
polyethylene terephthalate spacer. The nebuliser was left running forapproximately 2–3 min to prime the spacer and then connected to the
exposure line. The exposure and perfusate samplingwere started simul-
taneously (the autosampler changed tube every 30 s), the nebulisation
apparatuswas removedwhen the reservoirwas empty (which took 7 to
10 min) and the perfusion and ventilation of the IPRL was allowed to
continue for one hour. Finally, the lungs were removed from the cham-
ber and placed in an individual tissue tube (Covaris). The tissues were
immediately frozen and stored at−80 °C. The lungswere homogenised
using a focused ultrasonicator (Covaris). Homogenates were suspended
in an acetate buffer at pH 5.0 and analysed. Samples were spiked with
dexamethasone (used as internal standard), extracted with DCM, dried
and reconstituted in a 50/50 (v/v) mixture of acetonitrile and ultrapure
water, containing 0.1% formic acid. They were then analysed by tandem
mass spectrometry (LC-MS/MS, LC: Agilent 1100, MS: API 4000, Applied
Biosystems, using Analyst software). The limit of quantiﬁcation was
0.37 nM for all polymer based compounds and 1.6 nM for prednisolone.
2.6. Modelling and simulations
Drug concentrations measured in the perfusate were normalised to
the actual administered dose during the experiment. This was obtained
by adding up the remaining dose in the lungs at the end of the experi-
ment and the total dose recovered in the perfusate. Thus, relative drug
fractions (L−1) were used to compare the conjugate pharmacokinetics.
The relative Cmax was deﬁned as the maximum relative fraction
obtained and tmax as the time to reach Cmax. The apparent prednisolone
permeation rate constant was determined from the slope of the loga-
rithmic plot showing the fraction of prednisolone in perfusate with
time, after the initial administration of the free drug.
The Berkeley–Madonna software was employed to determine the
hydrolysis rate of the conjugates in the lungs according to the pharma-
cokinetic model presented in Fig. 1. In this model, prednisolone or the
conjugates were administered to the IPRL for 7 to 10 min at a constant
rate kin, following a zero-order kinetic process. The conjugates were
hydrolysed following a pseudo ﬁrst order kinetic process, at a rate con-
stant k1 for themonosubstituted PEG conjugate or k2 for the disubstitut-
ed conjugate. To account for the presence of esterases in the pulmonary
tissue, the model initially used Michaelis–Menten kinetics to describe
the conjugate hydrolysis. However, the plots displaying the logarithmic
of the decrease in prednisolone concentration in perfusate vs time after
the nebulisation was completed were linear for the two conjugates
(data not shown). This indicated that the rate of hydrolysis of the conju-
gates was dependent on their concentration in the lung ﬂuid. It could
therefore be assumed that, over the course of the absorption study,
the concentration of the conjugates in the lungs was always lower
than the Michaelis constant Km. In this case, the hydrolysis kinetics is
a pseudo ﬁrst order process. Finally, prednisolone was absorbed from
the lungs into the perfusate following a ﬁrst order kinetic process with
a rate constant kout. A simulationwas also performed using an adminis-
tration time of 5 min and the rate constants previously determined in
order to evaluate the inﬂuence of prednisolone conjugation on tmax.
2.7. Statistical analysis
One tailed Student's t-tests were applied to evaluate the signiﬁcance
of the difference between two sets of values. Statistical signiﬁcance was
set at 95% conﬁdence intervals (p b 0.05).
3. Results
3.1. Synthesis of the PEG-prednisolone conjugates
Prednisolone being devoid of a carboxyl group that could react with
PEG hydroxyl groups to form ester conjugates, PEG terminal groups
were ﬁrst converted into carboxylic acids. PEG oxidation was complete
for all molecular weights investigated (data not shown). Esters of
Fig. 1.Model used to describe absorption studies in the IPRL. kin: zero order rate constant
for the drug administration, kout: ﬁrst order permeation rate constant of prednisolone, k1:
pseudo ﬁrst order hydrolysis rate constant ofmPEG-Pred, k2: pseudoﬁrst order hydrolysis
rate constant of PEG-Pred2.
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and thoroughly characterised.
FTIR spectra of the conjugates showed the presence of prednisolone
characteristic peaks at 1659 cm−1, 1614 cm−1 and 1419 cm−1 as well
as a peak at 1761 cm−1 corresponding to an ester link (Fig. 2). NMR
data indicated that PEG conjugations reached 100% (Table 1), providing
dry material and glassware were employed, and the reactions were
allowed to pursue until completion. The expected difference inmolecular
weight between oxidised PEG/mPEG and the corresponding conjugates
was measured by mass spectrometry, which conﬁrmed the molecular
composition of the conjugates (Table 1). Elemental analysis revealed the
absence of contaminants in the puriﬁed products (Table 1). The synthetic
yields ranged between 58 and 75% depending on PEG molecular weight
and the puriﬁcation procedure (Table 1).
3.2. Hydrolysis of the conjugates in buffers
Autohydrolysis of the different conjugates was evaluated in buffers
at pH 6.2, 7.4 and 8.0 in order to encompass the range of pH reported
in the literature for the lung ﬂuid [23–25].
The hydrolysis rate of all four conjugates was pH dependent with a
faster degradation at alkaline pH (Table 2), which is consistent with the
well recognised base-catalysed hydrolysis mechanism of esters. At each
pH studied, the t1/2 of the three disubstituted conjugates lied between 6
and 18% of each other (Table 2), indicating that the length of the PEG
chain did not affect their aqueous stability. In contrast, the calculated t1/
2 of the monosubstituted conjugate was twice as high (Table 2).
3.3. Cytotoxicity assays in Calu-3 cells
LDH released fromCalu-3 cellswasmeasured following a 20 h expo-
sure to prednisolone or the conjugates.Fig. 2. FTIR spectra of PEG-prednisolone conjugates. From top to bottom: PEG1000-Pred2,
PEG2000-Pred2, mPEG2000-Pred, PEG3400-Pred2.Prednisolone and the conjugates of 1000 and 2000 Da were not cy-
totoxic up to 500 μM or 1000 μM (highest concentrations achievable
with 1% ethanol in the culture medium), respectively (Fig. 3; data not
shown for prednisolone). However, the % of LDH released from Calu-3
cells exposed to PEG3400-Pred2was signiﬁcantly higher than the sponta-
neous release from untreated cells at concentrations ≥1 μM (Fig. 3;
p b 0.05). This conjugate was therefore considered unsafe and hence,
was not evaluated in the subsequent IPRL absorption studies. Although
the PEG1000 conjugate appeared non cytotoxic in the assay, it was a
waxy material that would eventually be extremely challenging to for-
mulate as an inhalation product and thus, was also abandoned at this
stage.
3.4. Absorption studies in the IPRL
The ability of the two conjugates PEG2000-Pred2 and mPEG2000-Pred
to inﬂuence the pulmonary absorption of prednisolone was assessed in
an IPRLmodel. In order to negate the effect of dissolution rate on pulmo-
nary absorption, the different compounds were administered as solu-
tions for nebulisation.
The drug and conjugates were nebulised to the IPRL over 7–10 min.
1.9 ± 0.9%, 0.2 ± 0.0% or 1.6 ± 0.9% of the dose loaded in the nebuliser
was delivered to the lung preparation for prednisolone, mPEG2000-Pred
or PEG2000-Pred2, respectively, the lower delivery efﬁciency observed
with the monosubstituted conjugate being likely due to differences in
the solution properties such as hydrophilicity, viscosity or surface
tension.
Once the administration of prednisolone was terminated, the drug
concentration in the perfusate decreased rapidly andwas notmeasurable
beyond 20 min post-dosing (Fig. 4). In contrast, when the conjugates
were aerosolised, prednisolonewas still detectable in the perfusion buffer
40 min post-dosing (Fig. 4). Neither PEG nor the conjugates could be
quantiﬁed in the perfusate throughout the time of the absorption studies.
Besides, at the end of the 60 min perfusion time, a maximum of 0.93% or
3.25% of the delivered dose were recovered in the lungs as conjugates or
prednisolone, respectively.
The conjugates reduced the relative Cmax by a 2.2 and 3.0 fold, re-
spectively for mPEG2000-Pred and PEG2000-Pred2 (Table 3; p b 0.05)
with, moreover, a signiﬁcantly lower relative Cmax obtained for the di-
substituted conjugate than for the monosubstituted (Table 3;
p b 0.05). The time to reach Cmax, so called tmax, was difﬁcult to deter-
mine accurately due to the variability in nebulisation times. Additional-
ly, the half-live of prednisolone absorption in the perfusate was
prolonged 4.2 and 7.7 times with mPEG2000-Pred or PEG2000-Pred2, re-
spectively (Table 3; p b 0.05).
3.5. Modelling and simulations
Due to the lack of a technique capable of accurately measuring local
concentrations in the lungs, mathematical simulations have recently
been exploited to estimate pulmonary drug concentrations after inhala-
tion [26,27]. Similarly, in this study, the model presented in Fig. 1 was
used to simulate the hydrolysis of the conjugates in the lung ﬂuid.
The model determined the rate of prednisolone pulmonary absorp-
tion kout as 0.485 ± 0.054 min−1 (mean ± SD, n = 3). This was used
to calculate the hydrolysis rate constant and hydrolysis t1/2 of the two
conjugates in the lungs (Table 3). The model indicated that the
monosubstituted conjugate was hydrolysed faster in the lungs than
the disubstituted product (Table 3).
It is noteworthy that simulated values for relative Cmax were within
4% of the experimental values (Table 3) and the simulated proﬁles of
prednisolone fraction in the perfusate mimicked the experimental
data (Fig. S1, supplementary information), illustrating the robustness
of the model.
Simulations were ﬁnally exploited to determinewhether the con-
jugates were able to delay tmax. Using a ﬁxed administration time of
Table 1
Characterisation of PEG-prednisolone conjugates.
Type Formula Average MW (Da) NMRa Elemental analysis Mass spectrometry Synthetic yield (%)
Meas % Th % Meas Δmass (Da) Th Δmass (Da)
PEG1000-Pred2 C86H138O33 1700 1.91 % C: 58.3 % C: 57.0 684.2 684.9 69
% H: 8.1 % H: 8.7
% N:−0.3 % N: 0
PEG2000-Pred2 C136H238O58 2801 2.07 % C: 57.1 % C: 58.3 685.5 684.9 60
% H: 8.0 % H: 8.5
% N: 0 % N: 0
mPEG2000-Pred C116H216O53 2459 0.99 % C: 56.3 % C: 56.5 342.6 342.4 58
% H: 8.8 % H: 8.8
% N:−0.1 % N: 0
PEG3400-Pred2 C194H354O87 4079 1.94 % C: 55.9 % C: 57.0 685.3 684.9 75
% H: 8.1 % H: 8.7
% N: 0.2 % N: 0
a Mol of Pred/mol of PEG, Meas: measured, Th: theoretical, Δmass: mass difference between oxidised PEG/mPEG and the corresponding conjugates.
238 F.J.C. Bayard et al. / Journal of Controlled Release 171 (2013) 234–2405 min in the model, tmax was indeed increased from 5 min with free
prednisolone to 6.6 min and 7.25 min with mPEG2000-Pred and
PEG2000-Pred2, respectively (Fig. S1, supplementary information).4. Discussion
A major challenge in drug inhalation remains to optimise the phar-
macokinetic proﬁle of low molecular weight compounds used in the
management of asthmaor COPD. Indeed, inhaled drugs are often rapidly
absorbed from the lungs into the bloodstream, therefore causing sys-
temic adverse effects and requiring frequent administrations to com-
pensate for the short duration of pharmacological action locally [2].
Current approaches to increase drug residence time in the lungs typical-
ly rely on poorly soluble or biodegradable polymeric particles [2]. How-
ever, these are commonly associated with lung irritancy or local
accumulation with unknown long-term effects [2,13]. PEGylation is ex-
tensively exploited to increase the circulating time of therapeutics ad-
ministered by the parenteral route [16]. In contrast, this has not yet
been explored as a strategy for extending the pulmonary retention of
small inhaled molecules whereas it might represent a safer and more
versatile alternative to engineered slow-dissolving particles.
This study assessed the feasibility of conjugating PEG to a model
inhaled drug through a simple hydrolysable ester bond to retard its sys-
temic absorption after pulmonary delivery. Ester conjugates of PEG1000,
PEG2000, mPEG2000, PEG3400 and prednisolone produced were stable in
aqueous buffers and at the exception of PEG3400-prednisolone, were
non cytotoxic to human bronchial epithelial cells in the LDH assay. Fol-
lowing nebulisation to IPRL, PEG2000 and mPEG2000 conjugates were
able to reduce prednisolone Cmax in the perfusate and increase its resi-
dency in the pulmonary tissue, thus demonstrating the high potential
of PEGylation as a novel strategy for controlling the systemic absorption
of inhaled small compounds.
The pharmacokinetic proﬁles of prednisolone administered alone or
as PEG conjugates were determined in an IPRL model. IPRL systems
have gained a renewed popularity recently as pulmonary absorption
rates obtained correlate with in vivo pulmonary absorption parametersTable 2
Half-lives (hours) of PEG-prednisolone conjugates at different pH.
Conjugate pH 6.2 pH 7.4 pH 8.0
PEG1000-Pred2 38.37 ± 1.38 2.84 ± 0.05 0.91 ± 0.01
PEG2000-Pred2 33.94 ± 0.20 2.97 ± 0.01 1.00 ± 0.02
mPEG2000-Pred 73.28 ± 0.17 5.58 ± 0.03 2.01 ± 0.03
PEG3400-Pred2 40.12 ± 0.60 3.02 ± 0.02 0.94 ± 0.001
pH 6.2 and 7.4: Mc Ilvaine buffer, pH 8.0: phosphate buffer, μ = 0.5. Data are displayed as
the average of n = 3 ± SD.while the technique is more ethical than studies in laboratory animals
[28,29]. In addition, a single-pass perfusate mode satisﬁes a sink-
condition within the lung vascular bed. Hence, IPRL time-concentration
proﬁles manifest a simpliﬁed but yet informative deconvolution of the
total absorbed dose as a function of timewithout the need for total clear-
ance rates [29].
The absorption rate of prednisolone across the pulmonary barrier
was decreased 4.2 and 7.7 times following conjugation with mPEG2000
and PEG2000, respectively (Table 3). This resulted in an improved phar-
macokinetic proﬁle exhibiting a lower Cmax and a more sustained ab-
sorption (Fig. 3). Nevertheless, Cmax was still reached in less than
10 min (Fig. 3) due to the conjugates being cleaved within a few mi-
nutes in the lungﬂuid (Table 3). As thesewere considerablymore stable
in buffers (Table 2), their rapid degradation in physiological conditions
can be explained by the presence of esterases in the lungs [30,31]. A
higher esterase activity has previously been observed in rat lung slices
as compared to their human counterparts [32]. Therefore, IPRL data
might not predict the extent of prednisolone retention in human
lungs. However, the esterase activity of the lungs offers the opportunity
for optimising the pharmacokinetic parameters of individual inhaled
drugs through the design of drug ester conjugates with various suscep-
tibilities to enzymatic cleavage. As described previously, this could be
achieved by addition of different chemical spacers between the active
molecule and the polymer [33,34].
Interestingly, PEG2000-prednisolone was more stable in the lung
ﬂuid than the mPEG2000 equivalent (Table 3) while the hydrolysis rate
of the monosubstituted conjugate was the slowest in aqueous buffers
(Table 2). It can be hypothesised that this self-assembled into micelles
at the high concentration used in the hydrolysis study in buffers, as re-
cently reported for conjugates of mPEG3500 and the hydrophobic com-
pound embelin [35], the terminal prednisolone playing the role of a
lypophilic head and the PEG chain of a hydrophilic tail. The ester link
would therefore have been protected within the micellar structure,
thus enhancing the aqueous stability of this conjugate.
PEG of molecular weight b5 kDa were used as conjugating polymers
in this study as these were shown to be slowly absorbed into the blood-
stream after intratracheal delivery to rats while being cleared from the
airways within 48 h [15]. For instance, 90% of the PEG2000 dose was elim-
inated from the lungs within 24 h [15]. Oxidised PEG2000 released from
our lead conjugate is likely to have a shorter pulmonary elimination
half-live since a faster permeation rate across IPRL has been reported for
negatively charged inhaledmacromolecules as compared to neutral com-
pounds of similar molecular size [36]. Provided a once daily administra-
tion can be achieved through optimisation of the conjugate structure,
limited accumulation in the lungs is therefore expected upon repeated
administrations. Following absorption into the systemic circulation, it
can be hypothesised that, like PEG2000, carboxyl PEG2000 will be
eliminated through renal ﬁltration [16]. Although toxicological
BC D
A
Fig. 3. Cytotoxicity proﬁles of PEG-prednisolone conjugates. A. PEG1000-Pred2, B. PEG2000-Pred2, C. mPEG2000-Pred, D. PEG3400-Pred2. Data are presented as mean ± SD (n = 6); hatched
lines represent the spontaneous LDH release ± SD; * indicate a statistically signiﬁcant increase in LDH release as compared to untreated cells (p b 0.05).
239F.J.C. Bayard et al. / Journal of Controlled Release 171 (2013) 234–240concerns arise from a possible polymer accumulation in the lungs, the
safety of PEG3400 has been demonstrated in rats following a 2 week
aerosol exposure [37]. However, the correspondingprednisolone conju-
gate was toxic to Calu-3 cells at relatively low concentrations (Fig. 2).
This could be due to the oxidised polymer released upon hydrolysis
of the conjugate. The 2 kDa conjugates tested in the IPRL were,Fig. 4. Normalised absorption proﬁles of prednisolone in the IPRL obtained with (□)
prednisolone alone, (○) mPEG2000-Pred and (Δ) PEG2000-Pred2. Prednisolone
concentration (nmol L−1) measured in perfusate was divided by the actual delivered
dose (nmol) to give a relative prednisolone fraction (L−1). Data are presented as
mean ± SD, n = 3.conversely, not cytotoxic over the concentration range investigated
(Fig. 2). Furthermore, these did not cause any acute alteration of the
IPRL absorption barrier since no compound other than prednisolone
could be detected in the perfusate. Considering the present scarcity of
toxicity data following pulmonary delivery of PEG, long-term studies
are nevertheless required before the safety of inhaled PEG-drug conju-
gates can be ascertained.5. Conclusions
This proof-of-concept study demonstrates, for the ﬁrst time, the po-
tential of hydrolysable polymeric drug ester conjugates for prolonging
the retention of small molecules in situ following inhalation. Conjuga-
tionwith PEG2000 through a simple ester linkwas proven effective in de-
creasing the rate of drug pulmonary absorption. This strategy appears
therefore highly promising for improving the pharmacokinetics of in-
haled drugs and reducing their systemic adverse effects. However, due
to the esterase activity in the pulmonary tissue, more hindered linkers
are likely to be required for achieving a sustained drug release in the
lungs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jconrel.2013.07.023.Acknowledgements
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Table 3
Observed/modelled pharmacokinetic parameters and simulated hydrolysis parameters.
Compound Observed Modelled/simulated
Cmax (L−1)
Permeation
Cmax (L−1)
Hydrolysis
k (min−1) t1/2 (min) k (min−1) t1/2 (min)
Prednisolone 9.13 ± 1.37 0.694 ± 0.107 1.02 ± 0.17 9.09 NA NA
mPEG2000-Pred 4.22 ± 0.20 0.164 ± 0.026 4.30 ± 0.70 4.27 0.157 ± 0.002 4.4
PEG2000-Pred2 3.08 ± 0.22 0.090 ± 0.010 7.81 ± 0.88 3.19 0.101 ± 0.013 6.9
Data are displayed as the average of n = 3 ± SD. NA: not applicable.
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